title: Incidence of steroid-induced ocular hypertension after vitreoretinal surgery with difluprednate versus prednisolone acetate.
abstract: OBJECTIVE
  To identify changes in intraocular pressure (IOP) after vitreoretinal surgical procedures in eyes that received either difluprednate ophthalmic emulsion 0.05% (DP) or prednisolone acetate ophthalmic suspension 1% (PA).
  
  
  METHODS
  A retrospective chart review compared a consecutive series of 100 patients who received DP with 100 patients who received PA after vitreoretinal surgery. Data were collected for a 3-month period from the time of surgery.
  
  
  RESULTS
  A significantly higher number of patients treated with DP (35%, n = 35) developed increased IOP (>21 mmHg with a change from baseline of >10 mmHg) compared with those receiving PA (22%, n = 22) (P = 0.042). The mean maximum IOP in the DP cohort (26.7 mmHg) was significantly higher than that in the PA cohort (22.8 mmHg) (P = 0.0027). Additionally, the rise in IOP from baseline was significantly higher in the DP-treated cohort (9.0 mmHg) than that in the PA-treated cohort (6.0 mmHg) (P = 0.027).
  
  
  CONCLUSIONS
  Eyes treated with DP after vitreoretinal surgery were at increased risk for developing clinically significant increases in IOP compared with those receiving PA.
authors.affiliation: *Rutgers-Robert Wood Johnson Medical School, Piscataway, New Jersey; †NJ Retina, New Brunswick, New Jersey; and ‡Emory Eye Center, Atlanta, Georgia.
authors.forename: Karen W
authors.initials: KW
authors.lastname: Jeng
authors.forename: Howard F
authors.initials: HF
authors.lastname: Fine
authors.forename: H Matthew
authors.initials: HM
authors.lastname: Wheatley
authors.forename: Daniel
authors.initials: D
authors.lastname: Roth
authors.forename: Daniel B
authors.initials: DB
authors.lastname: Connors
authors.forename: Jonathan L
authors.initials: JL
authors.lastname: Prenner
mesh_terms: D004655:Emulsions; D005260:Female; D005477:Fluprednisolone / Q000009:adverse effects / Q000031:analogs & derivatives*; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D015994:Incidence; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000139:chemically induced*; D011239:Prednisolone / Q000009:adverse effects / Q000031:analogs & derivatives*; D012189:Retrospective Studies; D012591:Scleral Buckling; D013535:Suspensions; D014065:Tonometry, Ocular; D014821:Vitrectomy; D057586:Vitreoretinal Surgery
chemical_list: D004655:Emulsions; D005938:Glucocorticoids; D013535:Suspensions; C009935:prednisolone acetate; D005477:Fluprednisolone; D011239:Prednisolone; C015808:difluprednate